[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200100165A1 - Применение усилителя захвата глюкозы для уменьшения апоптоза - Google Patents

Применение усилителя захвата глюкозы для уменьшения апоптоза

Info

Publication number
EA200100165A1
EA200100165A1 EA200100165A EA200100165A EA200100165A1 EA 200100165 A1 EA200100165 A1 EA 200100165A1 EA 200100165 A EA200100165 A EA 200100165A EA 200100165 A EA200100165 A EA 200100165A EA 200100165 A1 EA200100165 A1 EA 200100165A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
cells
reduce apoptosis
human
capture amplifier
Prior art date
Application number
EA200100165A
Other languages
English (en)
Inventor
Антуан Мишель Алан Бриль
Робин Эдвин Бакингэм
Нассира Кандуди
Original Assignee
Смитклайн Бичам Плс
Смитклайн Бичам Лаборатуар Фармасетик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Смитклайн Бичам Плс, Смитклайн Бичам Лаборатуар Фармасетик filed Critical Смитклайн Бичам Плс
Publication of EA200100165A1 publication Critical patent/EA200100165A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Способ уменьшения или предотвращения апоптоза дифференцированных клеток, выбранных из группы кардиомиоцитов, бета клеток поджелудочной железы, эндотелиальных клеток и нейрональных клеток человека и млекопитающих, включающий введение, включая кратковременное введение эффективного, нетоксичного количества усилителя захвата глюкозы человеку или млекопитающему, нуждающемуся в нем.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100165A 1998-07-21 1999-07-21 Применение усилителя захвата глюкозы для уменьшения апоптоза EA200100165A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
EA200100165A1 true EA200100165A1 (ru) 2001-08-27

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100165A EA200100165A1 (ru) 1998-07-21 1999-07-21 Применение усилителя захвата глюкозы для уменьшения апоптоза

Country Status (26)

Country Link
EP (2) EP1098639B1 (ru)
JP (1) JP2002521326A (ru)
KR (1) KR20010079551A (ru)
CN (1) CN1310620A (ru)
AP (1) AP2001002036A0 (ru)
AT (1) ATE288746T1 (ru)
AU (1) AU5053799A (ru)
BG (1) BG105250A (ru)
BR (1) BR9912117A (ru)
CA (1) CA2338211A1 (ru)
DE (1) DE69923687T2 (ru)
DK (1) DK1098639T3 (ru)
EA (1) EA200100165A1 (ru)
ES (1) ES2237929T3 (ru)
HK (1) HK1037865A1 (ru)
HU (1) HUP0103199A3 (ru)
ID (1) ID26986A (ru)
IL (1) IL140664A0 (ru)
NO (1) NO20010292L (ru)
OA (1) OA11579A (ru)
PL (1) PL345627A1 (ru)
PT (1) PT1098639E (ru)
SI (1) SI1098639T1 (ru)
SK (1) SK1012001A3 (ru)
TR (1) TR200100207T2 (ru)
WO (1) WO2000004890A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
KR20000036035A (ko) * 1996-09-12 2000-06-26 가와무라 요시부미 트로글리타존을 함유하는 글루타티온 환원효소 활성증강제
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
CA2311125C (en) * 1997-11-19 2011-01-18 Takeda Chemical Industries, Ltd. Apoptosis inhibitor
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
NO20010292D0 (no) 2001-01-18
SI1098639T1 (ru) 2005-08-31
CA2338211A1 (en) 2000-02-03
AU5053799A (en) 2000-02-14
DE69923687D1 (de) 2005-03-17
PL345627A1 (en) 2002-01-02
BG105250A (en) 2001-11-30
EP1098639A1 (en) 2001-05-16
HUP0103199A3 (en) 2002-08-28
ID26986A (id) 2001-02-22
HK1037865A1 (en) 2002-02-22
NO20010292L (no) 2001-03-08
ES2237929T3 (es) 2005-08-01
EP1098639B1 (en) 2005-02-09
OA11579A (en) 2004-06-01
SK1012001A3 (en) 2001-08-06
WO2000004890A1 (en) 2000-02-03
ATE288746T1 (de) 2005-02-15
DE69923687T2 (de) 2006-04-06
BR9912117A (pt) 2001-04-10
JP2002521326A (ja) 2002-07-16
KR20010079551A (ko) 2001-08-22
DK1098639T3 (da) 2005-06-13
CN1310620A (zh) 2001-08-29
EP1516617A2 (en) 2005-03-23
HUP0103199A2 (hu) 2002-05-29
IL140664A0 (en) 2002-02-10
TR200100207T2 (tr) 2001-05-21
PT1098639E (pt) 2005-06-30
AP2001002036A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
DK1066052T3 (da) Mesenchymstamceller til forebyggelse og behandling af immunreaktioner ved transplantationer
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
EA199901027A1 (ru) Сложные моноэфиры пробукола для лечения сердечно-сосудистых и воспалительных заболеваний
ID30181A (id) Asam antranilat- dan asam tioantranilat-n-aril amida
EA200200316A1 (ru) Соединения для лечения ишемии
EA200101089A1 (ru) Новый способ лечения
ATE71298T1 (de) Immunoregulation.
EE9800387A (et) Implantatsiooni tõhustamine pärast in vitro viljastamist
EA199900796A1 (ru) Стабильный экстракт зверобоя, способ его приготовления и фармацевтические составы на его основе
PT785948E (pt) Analogos do factor de crescimento de queratinocitos
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
ATE358473T1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
EP0682107A3 (en) Process for the long-term culture of cells of the dermal papilla.
PT888271E (pt) Derivados de benzamidina substituidos com derivados de aminoacidos e hidroxiacidos e sua utilizacao como anticoagulantes
IT1175868B (it) Amplificatore con conversione corrente-tensione, in particolare preamplificatore di ricevitore ottico
NO307788B1 (no) Glykogenpolysakkarider
DE69010482D1 (de) Unterhose.
EA200100165A1 (ru) Применение усилителя захвата глюкозы для уменьшения апоптоза
PT1067966E (pt) Composicao oftalmica compreendendo um bloqueador beta
DE69026435D1 (de) Chopper-Gegentaktoperationsverstärker mit Eintaktausgang
NO890356L (no) Fremgangsmaate til aa utfoere vei- og markkonstruksjoner.
DE3871198D1 (de) Leistungsverstaerker mit niedriger intermodulationsverzerrung.
FI880636A0 (fi) Foerfarande foer inaktivering av med hoelje foersedda virus i en medelst en cell in vitro framstaellda proteinprodukter.
NO954081L (no) Cytotoksisk faktor forbundet med disseminert sklerose, dens påvisning og kvantifisering